查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088992

人類免疫力缺乏病毒 (HIV) 治療市場：2026-2032 年全球市場預測（按藥物類別、治療線、給藥途徑、患者類型、病毒類型、最終用戶和分銷管道分類）

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Therapy Line, Route of Administration, Patient Type, Virus Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類免疫力缺乏病毒 (HIV) 治療市場規模將成長至 293.2 億美元，複合年成長率為 4.71%。

主要市場統計數據
基準年 2025 212.3億美元
預計年份：2026年 222.3億美元
預測年份 2032 293.2億美元
複合年成長率 (%) 4.71%

人類免疫力缺乏病毒（HIV）治療市場仍然是醫藥行業高度重視的領域，其發展受到對終身抗逆轉錄病毒療法、簡化治療方案以及全球治療目標日益成長的需求所驅動。根據聯合國愛滋病規劃署的數據，截至2023年，全球有3,990萬人感染HIV，其中3,070萬人正在接受抗逆轉錄病毒療法，凸顯了對有效HIV治療、藥物依從性支持和抗菌素抗藥性管理的巨大且持續的需求。

目前的治療方案包括基於整合酶鏈轉移抑制劑（IST）的療法、雙藥維持治療、長效注射HIV治療以及針對多重抗藥性患者的補救性治療。產業進步與持續病毒抑制、減少藥物交互作用、提高耐受性、差異化智慧財產權以及在高感染負擔地區和新興醫療體系中擴大藥物可近性密切相關。

愛滋病治療前景的變革性變化

目前，愛滋病治療正從每日服藥的負擔轉向以病人為中心、考慮抗藥性的長效治療。經FDA和EMA批准的卡博特韋和利匹韋林長效聯合治療，已被證實可作為病毒學抑製成人患者的注射維持療法。同時，來那卡帕韋透過每年兩次的衣殼抑制劑給藥方案，拓展了多重抗藥性愛滋病的治療選擇。

人工智慧對愛滋病治療的累積影響

人工智慧（AI）並非只是一種獨立的介入手段，而是對整體愛滋病治療領域產生累積影響。人工智慧驅動的分子建模、病毒定序和臨床試驗設計工具可以幫助識別目標、預測抗藥性並快速評估聯合治療，尤其在突變模式降低標準抗逆轉錄病毒療法療效時，這些工具能夠發揮顯著作用。

愛滋病治療的關鍵區域見解

在亞太地區，儘管治療需求旺盛，但可近性卻存在差異。中國、印度、日本、澳洲和韓國的醫保報銷體系、生產結構和創新特徵各不相同。印度在全球非專利抗逆轉錄病毒藥物的供應和可及性計畫中繼續發揮核心作用，而日本、澳洲和韓國則專注於高品質的專科護理、快速診斷以及新型愛滋病治療方案的可及性。中國正大力推動治療覆蓋範圍擴大和國內藥物創新，並輔以不斷擴大的公共衛生舉措和臨床研究活動。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等主要集團的發展趨勢

在東協市場，隨著各國政府擴大檢測、啟動治療和社區服務模式，愛滋病治療的重要性日益凸顯，但治療的可近性因收入水平、消除歧視和醫療基礎設施的不同而有所差異。海灣合作理事會（GCC）地區的特點是報告的患者數量相對較低，擁有完善的專業醫療體系，並且對創新型愛滋病治療的需求很高，這得益於公共資金支持、集中採購和醫院主導的治療路徑。

首選 HIV 治療藥物市場的關鍵國家洞察

美國在快速推廣品牌抗愛滋病藥物、開展臨床試驗、採納指南以及採用長效治療方案方面主導，這得益於其完善的專科藥房管道和聯邦政府的愛滋病應對舉措。在加拿大，全民健保和各省/地區處方藥清單相結合，形成了一種系統化的治療模式，但不同地區的藥物可近性存在差異。墨西哥和巴西則主要依靠公共部門的治療項目，其中巴西因其長期以來透過國家醫療服務體系免費提供抗逆轉錄病毒病毒藥物以及持續開展公共採購以支持愛滋病治療而備受讚譽。

為愛滋病治療產業領導者提供的實用建議

產業領導者應優先考慮差異化治療方案，以提高患者的用藥依從性，降低抗藥性風險，並滿足經驗豐富的患者群體未被滿足的需求。投資應集中於長效製劑、新型作用機制、適用於兒童和青少年患者的製劑，以及能夠減輕用藥負擔並同時保持高抗藥性閾值的聯合治療。

基於證據的愛滋病治療藥物分析調查方法

本執行摘要基於二手研究，參考了包括聯合國愛滋病資訊來源(UNAIDS)、世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 等公共衛生和監管機構的權威資料，以及各國愛滋病治療指南、同行評審的臨床文獻和公共採購及報銷資訊。市場分析重點關注檢驗的流行病學數據、已通過核准的治療類別、指南支持的治療路徑、已證實的可及性趨勢和可核實的監管里程碑。

結論：愛滋病治療藥物的未來

人類免疫力缺乏病毒（HIV）療法對公共衛生至關重要，並且仍然是一個充滿活力、創新主導的領域。推動這項需求的主要動力顯而易見：數以百萬計的人需要終身治療，而持續抑制病毒取決於能否獲得高效、耐受性良好、方便且價格合理的抗逆轉錄病毒藥物。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：免疫力缺乏病毒（HIV）治療市場：依藥物類別分類

  • 入侵抑制劑
    • 恩氟維替德
    • 馬拉威羅克
  • 整合酶/鏈轉移抑制劑
    • 比克替拉韋
    • 多替拉韋
    • 埃爾維特格拉維爾
    • 拉特格拉維爾
  • 非核苷類逆轉錄酶抑制劑
    • 依非韋倫
    • 依福西林
    • 奈韋拉平
    • 利匹韋林
  • 核苷類逆轉錄酶抑制劑
    • 阿巴卡韋
    • 恩曲他濱
    • 拉米夫定
    • 替諾福韋
    • 齊多夫定
  • 蛋白酶抑制劑
    • 阿扎那韋
    • 達蘆那韋
    • 福斯帕奈韋
    • 洛匹那韋

第8章：人類免疫力缺乏病毒（HIV）治療市場：依治療線分類

  • 聯合治療
    • 單片療法
    • 聯合治療
  • 單藥治療
  • 高效抗逆轉錄病毒療法
    • 一線治療
    • 二級治療
  • 暴露前預防
  • 暴露後預防

第9章：免疫力缺乏病毒（HIV）治療市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 皮下
    • 靜脈
  • 口服
    • 藥片
    • 膠囊
    • 解決方案
  • 外用

第10章：免疫力缺乏病毒（HIV）治療市場：依患者類型分類

  • 成人
  • 兒童
  • 老年人

第11章：免疫力缺乏病毒（HIV）治療市場：依病毒類型分類

  • HIV-1
  • HIV-2

第12章：免疫力缺乏病毒（HIV）治療市場：依最終用戶分類

  • 醫院
  • 居家照護環境
  • 愛滋病專科診所
  • 研究機構

第13章：人類免疫力缺乏病毒（HIV）治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：免疫力缺乏病毒（HIV）治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：免疫力缺乏病毒（HIV）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 人類免疫力缺乏病毒（HIV）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • CytoDyn Inc
  • Dr Reddy's Laboratories Limited
  • Emcure Pharmaceuticals Limited
  • F Hoffmann-La Roche AG
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Macleods Pharmaceuticals Limited
  • Merck & Co Inc
  • Pfizer Inc
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Limited
  • TaiMed Biologics Inc
  • Teva Pharmaceutical Industries Ltd
  • Theratechnologies Inc
  • Viatris Inc
  • ViiV Healthcare Limited
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E8CF6

The Human Immunodeficiency Virus Therapeutics Market is projected to grow by USD 29.32 billion at a CAGR of 4.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.23 billion
Estimated Year [2026] USD 22.23 billion
Forecast Year [2032] USD 29.32 billion
CAGR (%) 4.71%

Human immunodeficiency virus therapeutics remains a high-priority pharmaceutical segment shaped by lifelong antiretroviral therapy, rising demand for simplified regimens, and global treatment targets. UNAIDS reported 39.9 million people living with HIV in 2023, with 30.7 million receiving antiretroviral therapy, confirming a large and durable need for effective HIV drugs, adherence support, and resistance management.

The therapeutic landscape is anchored by integrase strand transfer inhibitor-based regimens, two-drug maintenance therapy, long-acting injectable HIV treatment, and salvage therapies for heavily treatment-experienced patients. Industry progress is increasingly linked to durable viral suppression, fewer drug interactions, improved tolerability, differentiated intellectual property, and broader access across high-burden and emerging healthcare systems.

Transformative Shifts in the HIV Therapeutics Landscape

The HIV therapeutics landscape is shifting from daily pill burden toward patient-centered, long-acting, and resistance-aware care. FDA- and EMA-approved long-acting cabotegravir plus rilpivirine has validated injectable maintenance therapy for virologically suppressed adults, while lenacapavir has expanded options for multidrug-resistant HIV through a twice-yearly capsid inhibitor approach.

Policy and procurement dynamics are also changing. WHO guidance favoring dolutegravir-based first-line regimens, growing adoption of differentiated service delivery, and expanding generic manufacturing have increased treatment coverage in low- and middle-income countries. At the same time, payer scrutiny in mature markets is pushing manufacturers to demonstrate adherence benefits, real-world durability, safety, and value versus lower-cost oral generics.

Cumulative Impact of Artificial Intelligence on HIV Therapeutics

Artificial intelligence is becoming a cumulative force across HIV therapeutics, not a standalone intervention. AI-enabled molecular modeling, viral sequence analysis, and trial design tools can support target identification, resistance prediction, and faster evaluation of combination therapies, especially where mutation patterns reduce response to standard antiretroviral therapy.

Commercial and clinical operations are also benefiting from AI. Predictive analytics can identify adherence risk, care gaps, and potential loss to follow-up, which is critical because sustained viral suppression prevents disease progression and transmission. However, AI adoption must be governed by validated datasets, privacy safeguards, bias monitoring, and clinical oversight to ensure tools improve outcomes rather than widen inequities.

Key Regional Insights for HIV Therapeutics

Asia-Pacific combines large treatment demand with uneven access, with China, India, Japan, Australia, and South Korea representing distinct reimbursement, manufacturing, and innovation profiles. India remains central to global generic antiretroviral supply and access programs, while Japan, Australia, and South Korea emphasize high-quality specialty care, rapid diagnosis, and access to novel HIV regimens. China is expanding treatment coverage and domestic pharmaceutical innovation, supported by public health initiatives and increasing clinical research activity.

North America remains a premium innovation region led by the United States and Canada, where rapid regulatory pathways, specialty pharmacy infrastructure, clinical trial density, and uptake of branded long-acting therapies support high-value therapeutic adoption. Europe benefits from centralized and national health technology assessment processes, broad treatment coverage, and strong clinical guideline alignment, though pricing discipline and comparative effectiveness reviews shape launch sequencing and reimbursement access.

Latin America, the Middle East, and Africa show rising demand tied to public-sector procurement, donor-supported programs, and national HIV strategies. Brazil has a mature public HIV treatment program and established domestic policy commitment to antiretroviral access, while GCC countries are expanding specialty care through public funding and centralized purchasing. Africa remains the global epidemiological center of HIV, with UNAIDS reporting that eastern and southern Africa carry the highest burden, making affordability, supply security, differentiated service delivery, and regimen simplification essential to treatment continuity.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for HIV therapeutics as governments expand testing, treatment initiation, and community-based service models, though access varies by income level, stigma reduction, and health infrastructure. The GCC is characterized by smaller reported patient populations, higher specialty-care capacity, and demand for innovative HIV therapies supported by public funding, centralized purchasing, and hospital-led treatment pathways.

The European Union and G7 remain influential because they shape HIV clinical standards, pricing benchmarks, pharmacovigilance expectations, health technology assessment requirements, and intellectual property strategies. NATO membership does not directly determine HIV demand, but overlapping high-income health systems often prioritize medicine security, supply-chain resilience, emergency preparedness, and continuity of care for chronic infectious diseases.

BRICS countries represent a strategic mix of scale, manufacturing capability, and epidemiological need. Brazil, India, China, Russia, and South Africa influence generic availability, public procurement, local production, clinical access negotiations, and national HIV program design, making the group central to long-term HIV treatment affordability, supply diversification, and patient access in both domestic and export-oriented markets.

Key Country Insights for Priority HIV Therapeutics Markets

The United States leads in branded HIV therapeutics, clinical trials, guideline adoption, and rapid uptake of long-acting regimens, supported by established specialty pharmacy channels and federal HIV initiatives. Canada combines universal health coverage with provincial and territorial formulary decision-making, creating structured but regionally varied access. Mexico and Brazil are driven by public-sector treatment programs, with Brazil recognized for longstanding free antiretroviral access through its national health system and continued use of public procurement to support HIV care.

The United Kingdom, Germany, France, Italy, and Spain have mature treatment networks, high viral suppression goals, routine guideline-based care, and rigorous reimbursement evaluation. Germany and France are key early-access and clinical adoption markets, while the United Kingdom emphasizes national guideline alignment and centralized health technology assessment. Italy and Spain maintain strong specialist HIV care networks. Russia faces substantial treatment need and distinct procurement dynamics, while China is expanding domestic innovation and treatment coverage. India remains pivotal as a global supplier of generic antiretroviral medicines and a major contributor to affordable HIV treatment access.

Japan, Australia, and South Korea represent advanced Asia-Pacific HIV therapeutics markets with strong clinical infrastructure, aging treated populations, and demand for therapies with favorable safety, interaction, renal, bone, metabolic, and adherence profiles. Australia also benefits from robust public health systems and prevention-oriented HIV policy, while South Korea and Japan continue to prioritize high-quality specialty care and access to clinically differentiated regimens.

Actionable Recommendations for HIV Therapeutics Leaders

Industry leaders should prioritize differentiated regimens that improve adherence, reduce resistance risk, and address unmet needs in treatment-experienced populations. Investment should focus on long-acting delivery, novel mechanisms, pediatric and adolescent-friendly formulations, and combinations that lower pill burden while preserving high barriers to resistance.

Commercial strategy must align innovation with access. Manufacturers should support voluntary licensing, regional manufacturing partnerships, pharmacovigilance capacity, and real-world evidence programs that demonstrate viral suppression, persistence, safety, and quality-of-life benefits. Payers and providers should integrate adherence analytics, community-based delivery, stigma-reduction initiatives, and resistance surveillance to maximize treatment impact.

Research Methodology for Evidence-Based HIV Therapeutics Analysis

This executive summary is grounded in secondary research from authoritative public health and regulatory sources, including UNAIDS, WHO, CDC, FDA, EMA, national HIV treatment guidelines, peer-reviewed clinical literature, and public procurement and reimbursement information. Market interpretation emphasizes validated epidemiology, approved therapeutic classes, guideline-supported care pathways, documented access trends, and observable regulatory milestones.

The analysis applies triangulation across disease burden, treatment coverage, regulatory approvals, clinical adoption, payer behavior, health-system capacity, and regional access mechanisms. No unsupported market-size, market-share, or forecasting claims are used; conclusions are based on verified evidence, approved products, published guidance, and consistent signals from public health programs and pharmaceutical activity.

Conclusion: The Future of HIV Therapeutics

Human immunodeficiency virus therapeutics remains a resilient, innovation-led field with significant public health importance. The core demand driver is clear: millions of people require lifelong therapy, and sustained viral suppression depends on access to potent, tolerable, convenient, and affordable antiretroviral options.

Future competitiveness will be defined by long-acting HIV treatment, resistance solutions, equitable access, AI-supported care optimization, and credible real-world outcomes. Organizations that combine scientific differentiation with affordability, supply reliability, and delivery innovation will be best positioned to support global HIV control objectives and create durable therapeutic value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

  • 7.1. Entry Inhibitors
    • 7.1.1. Enfuvirtide
    • 7.1.2. Maraviroc
  • 7.2. Integrase Strand Transfer Inhibitors
    • 7.2.1. Bictegravir
    • 7.2.2. Dolutegravir
    • 7.2.3. Elvitegravir
    • 7.2.4. Raltegravir
  • 7.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 7.3.1. Efavirenz
    • 7.3.2. Etravirine
    • 7.3.3. Nevirapine
    • 7.3.4. Rilpivirine
  • 7.4. Nucleoside Reverse Transcriptase Inhibitors
    • 7.4.1. Abacavir
    • 7.4.2. Emtricitabine
    • 7.4.3. Lamivudine
    • 7.4.4. Tenofovir
    • 7.4.5. Zidovudine
  • 7.5. Protease Inhibitors
    • 7.5.1. Atazanavir
    • 7.5.2. Darunavir
    • 7.5.3. Fosamprenavir
    • 7.5.4. Lopinavir

8. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line

  • 8.1. Combination Therapy
    • 8.1.1. Single Tablet Regimen
    • 8.1.2. Multi Tablet Regimen
  • 8.2. Monotherapy
  • 8.3. Highly Active Antiretroviral Therapy
    • 8.3.1. First-Line Therapy
    • 8.3.2. Second-Line Therapy
  • 8.4. Pre-Exposure Prophylaxis
  • 8.5. Post-Exposure Prophylaxis

9. Human Immunodeficiency Virus Therapeutics Market, by Route of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Subcutaneous
    • 9.1.3. Intravenous
  • 9.2. Oral
    • 9.2.1. Tablets
    • 9.2.2. Capsules
    • 9.2.3. Solutions
  • 9.3. Topical

10. Human Immunodeficiency Virus Therapeutics Market, by Patient Type

  • 10.1. Adult
  • 10.2. Pediatric
  • 10.3. Geriatric

11. Human Immunodeficiency Virus Therapeutics Market, by Virus Type

  • 11.1. HIV-1
  • 11.2. HIV-2

12. Human Immunodeficiency Virus Therapeutics Market, by End User

  • 12.1. Hospitals
  • 12.2. Homecare Settings
  • 12.3. Specialty HIV Clinics
  • 12.4. Research Institutes

13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Human Immunodeficiency Virus Therapeutics Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Human Immunodeficiency Virus Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Immunodeficiency Virus Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc
  • 18.2. Aspen Pharmacare Holdings Limited
  • 18.3. Aurobindo Pharma Limited
  • 18.4. Boehringer Ingelheim International GmbH
  • 18.5. Bristol-Myers Squibb Company
  • 18.6. Cipla Limited
  • 18.7. CytoDyn Inc
  • 18.8. Dr Reddy's Laboratories Limited
  • 18.9. Emcure Pharmaceuticals Limited
  • 18.10. F Hoffmann-La Roche AG
  • 18.11. Gilead Sciences Inc
  • 18.12. GlaxoSmithKline plc
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Hetero Labs Limited
  • 18.15. Johnson & Johnson Services Inc
  • 18.16. Lupin Limited
  • 18.17. Macleods Pharmaceuticals Limited
  • 18.18. Merck & Co Inc
  • 18.19. Pfizer Inc
  • 18.20. Strides Pharma Science Limited
  • 18.21. Sun Pharmaceutical Industries Limited
  • 18.22. TaiMed Biologics Inc
  • 18.23. Teva Pharmaceutical Industries Ltd
  • 18.24. Theratechnologies Inc
  • 18.25. Viatris Inc
  • 18.26. ViiV Healthcare Limited
  • 18.27. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENFUVIRTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENFUVIRTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENFUVIRTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MARAVIROC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MARAVIROC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MARAVIROC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BICTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BICTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BICTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ELVITEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ELVITEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ELVITEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RALTEGRAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RALTEGRAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RALTEGRAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EFAVIRENZ MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EFAVIRENZ MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EFAVIRENZ MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ETRAVIRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEVIRAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEVIRAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEVIRAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RILPIVIRINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RILPIVIRINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RILPIVIRINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ABACAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ABACAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ABACAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMTRICITABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMTRICITABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EMTRICITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LAMIVUDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LAMIVUDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LAMIVUDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TENOFOVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TENOFOVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TENOFOVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ZIDOVUDINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ZIDOVUDINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ZIDOVUDINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATAZANAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ATAZANAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATAZANAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DARUNAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DARUNAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DARUNAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LOPINAVIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LOPINAVIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LOPINAVIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SINGLE TABLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTI TABLET REGIMEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRE-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POST-EXPOSURE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HIV-1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV-1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HIV-1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV-2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HIV-2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV-2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SPECIALTY HIV CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 299. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 300. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 304. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET